South Korea
Following its successful launch last year, UBM EMEA's CPhI Korea returns with three times the exhibition space to the COEX in Seoul, South Korea, on 7–9 September 2015.
Co-organised by the Korean Pharmaceutical Traders Association, the event will be co-located with ICSE, P-MEC and BioPh, allowing global suppliers of raw materials, machinery, contract services and bio-solutions to interact with international visitors and deliver pharmaceutical products across Asia and the wider globe.
The pharmaceutical economy in South Korea is expected to reach a value of over $24 billion by 2020and following the country’s Pharma 2020 Vision, the Government has committed $8.9 billion to drug development over the next five years. Investment in biotechnology is increasing, with annual double-digit growth expected over the coming years. Most significantly, South Korea has the largest number of biosimilar clinical trials and targets in its pipeline.
Last year, South Korea reached a milestone in joining the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), which allowed domestic companies in the South Korean pharma industry to advance into foreign markets.
Over 3,000 attendees and 150 exhibitors from an estimated 50 countries are set to gather in South Korea for CPhI Korea's return.